Patents Assigned to Genentech
  • Patent number: 12115015
    Abstract: The present disclosure relates to techniques for segmenting tumors with positron emission tomography (PET) using deep convolutional neural networks for image and lesion metabolism analysis.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: October 15, 2024
    Assignee: GENENTECH, INC.
    Inventors: Nils Gustav Thomas Bengtsson, Richard Alan Duray Carano, Alexander James Stephen Champion de Crespigny, Jill Osborn Fredrickson, Mohamed Skander Jemaa
  • Publication number: 20240336697
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody, chemotherapy and a corticosteroid.
    Type: Application
    Filed: August 2, 2022
    Publication date: October 10, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jamie Harue HIRATA, Calvin Ka Yin LEE, Huan JIN, Lijia WANG, Jiaheng QIU, Qingxiang YAN
  • Publication number: 20240336625
    Abstract: Described herein are sulfonimidamide compounds, solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing. Further described herein are methods of treating a disorder in a subject in need thereof using said compounds, solvates, tautomers, or pharmaceutically acceptable salts thereof, such as NLRP3-mediated disorders.
    Type: Application
    Filed: July 15, 2022
    Publication date: October 10, 2024
    Applicant: Genentech, Inc.
    Inventors: Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Craig STIVALA
  • Patent number: 12110276
    Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: October 8, 2024
    Assignee: GENENTECH, INC.
    Inventors: Jason Robert Zbieg, Russell Tyler Smith, Paul Powell Beroza, Vishal Anil Verma, Bing-Yan Zhu, Ramsay Beveridge, Lisa Marie Barton, Bryan Ka Ip Chan, Curtis Colwell, Samir Bouayad-Gervais, Anwesha Dey, Marie Anne Evangelista
  • Patent number: 12110341
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: April 19, 2024
    Date of Patent: October 8, 2024
    Assignee: Genentech, Inc.
    Inventors: Reed J. Harris, Paul A. Motchnik
  • Publication number: 20240327522
    Abstract: Provided herein are anti-?v?8 antibodies or antigen-binding portions thereof and methods of making and using the same. Further provided are methods of treating cancer with an anti-?v?8 and a PD-1 axis antagonist.
    Type: Application
    Filed: March 29, 2024
    Publication date: October 3, 2024
    Applicant: Genentech, Inc.
    Inventors: WeiYu LIN, Kelly Michele LOYET, Matthieu MASUREEL, Minh THAI, Shannon Jennifer TURLEY, Tulika TYAGI, Yan WU, Jianhuan ZHANG, Alessandra CASTIGLIONI, Cecilia Pui Chi CHIU
  • Publication number: 20240325559
    Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
    Type: Application
    Filed: April 7, 2023
    Publication date: October 3, 2024
    Applicant: Genentech, Inc.
    Inventors: Ankit R. PATEL, Jun LIU
  • Publication number: 20240327528
    Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
    Type: Application
    Filed: March 19, 2024
    Publication date: October 3, 2024
    Applicant: Genentech, Inc.
    Inventors: Minhong Yan, Gu Zhang, Nicholas John Agard, Danielle Marie DiCara, Philip E. Hass, Julie Q. Hang, Erin L. Christensen, Robert Paul Morse, Sarah Sanowar, Vittal Shivva
  • Patent number: 12103975
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: October 1, 2024
    Assignee: Genentech, Inc.
    Inventors: Martin Gawlitzek, Shun Luo, Christina Teresa Bevilacqua
  • Publication number: 20240317738
    Abstract: Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
    Type: Application
    Filed: August 25, 2023
    Publication date: September 26, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Cheol Keun CHUNG, Jie XU, Hans IDING, Kyle CLAGG, Michael DALZIEL, Alec FETTES, Francis GOSSELIN, Ngiap-Kie LIM, Andrew MCCLORY, Haiming ZHANG, Paroma CHAKRAVARTY, Karthik NAGAPUDI, Sarah ROBINSON
  • Patent number: 12098365
    Abstract: The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: September 24, 2024
    Assignee: GENENTECH, INC.
    Inventors: Michael Wilson Laird, Shahram Misaghi, Amy Shen, Anthony Tomlinson, Inn Huam Yuk
  • Patent number: 12098426
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 24, 2024
    Assignee: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • Patent number: 12099064
    Abstract: The invention provides anti-hypusine antibodies and their use in detecting and isolating polypeptides containing hypusine and/or deoxyhypusine, as well as compositions and kits comprising the anti-hypusine antibodies.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: September 24, 2024
    Assignee: GENENTECH, INC.
    Inventors: Qianting Zhai, Paul J. Carter
  • Patent number: 12098211
    Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: September 24, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Publication number: 20240309088
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: December 21, 2023
    Publication date: September 19, 2024
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Publication number: 20240309314
    Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
    Type: Application
    Filed: November 13, 2023
    Publication date: September 19, 2024
    Applicant: Genentech, Inc.
    Inventors: Masaru Ken SHIRATORI, Robert David KISS, Hardayal PRASHAD, Raquel IVERSON, Justin BOURRET, Michael KIM, Salim CHARANIYA
  • Patent number: 12090211
    Abstract: The subject matter described herein is directed to methods of preparing certain antibody-drug conjugates (ADCs) wherein the antibody is linked to the drug through a linker, wherein the drug contains a heteroaryl group having a secondary nitrogen, and the linker is attached to the drug via the secondary nitrogen. The resulting conjugates are useful in treating various diseases and conditions.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: September 17, 2024
    Assignee: Genentech, Inc.
    Inventors: Thomas Pillow, Peter Dragovich
  • Publication number: 20240299392
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.
    Type: Application
    Filed: May 14, 2024
    Publication date: September 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Marie EVANGELISTA, Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Ting-Kun Mark LIN, Stephanie Royer JOO, Sandhya Vinayak MANDLEKAR, Stuart G. LUTZKER
  • Publication number: 20240300974
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
    Type: Application
    Filed: November 21, 2023
    Publication date: September 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Snahel PATEL, Gregory HAMILTON, Guiling ZHAO, Huifen CHEN, Blake DANIELS, Craig STIVALA
  • Patent number: D1042821
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: September 17, 2024
    Assignee: Genentech, Inc.
    Inventors: Hemanth Kumar Amarchinta, Bryan Andrew Click, Adam Daniel Farchone, Geoffrey Colin Wise